Alexion Pharma (ALXN) Could Consider Buying Ra Pharmaceuticals (RARX) Outright - RBC

RBC Capital analyst Kennen MacKay said Ra Pharmaceuticals (NASDAQ: RARX) Zilucoplan gMG data should impress even the skeptics and suggests while it is still several years from market, Alexion Pharma (NASDAQ: ALXN) could consider outright buying RARX.

"Given ALXN’s focus on Soliris/ALXN1210 expansion into gMG and additional potential mechanisms to target the gMG market (SyntImmune’s FcRn-targeted antibody) we anticipate that as RARX gets closer to commercialization ALXN could have strategic interest in a RARX acquisition, with sufficient financial flexibility to pursue a deal," he comments.

You May Also Be Interested In

• Roth/MKM Upgrades Albertsons Companies Inc. (ACI) to Buy, 'Fundamental Floor and Improved Deal Likelihood'
• Micron Technology (MU) plans to construct a $100B "Megafab" employing more than 9,000 workers in Upstate NY - Nikkei
• Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy